79,101 Shares in Puma Biotechnology, Inc. $PBYI Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 79,101 shares of Puma Biotechnology, valued at approximately $234,000, increasing its stake to 0.16% by the end of the recent quarter.
• The stock has seen a 1.6% decline, opening at $5.03 and showcasing a market cap of $253.36 million, with a price-to-earnings ratio of 5.13.
• Analysts have upgraded Puma Biotechnology from a "buy" to a "strong-buy" rating, with an average target price of $7.00 according to current consensus ratings.

Nuveen LLC acquired a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 79,101 shares of the biopharmaceutical company's stock, valued at approximately $234,000. Nuveen LLC owned 0.16% of Puma Biotechnology at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Puma Biotechnology during the 1st quarter worth $93,000. Invesco Ltd. raised its stake in shares of Puma Biotechnology by 88.9% in the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company's stock valued at $111,000 after purchasing an additional 17,707 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Puma Biotechnology by 70.6% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company's stock valued at $2,462,000 after purchasing an additional 344,321 shares during the period. Deutsche Bank AG acquired a new stake in shares of Puma Biotechnology in the 1st quarter valued at about $91,000. Finally, XTX Topco Ltd raised its stake in shares of Puma Biotechnology by 110.0% in the 1st quarter. XTX Topco Ltd now owns 125,317 shares of the biopharmaceutical company's stock valued at $371,000 after purchasing an additional 65,643 shares during the period. Institutional investors and hedge funds own 61.29% of the company's stock.

Puma Biotechnology Stock Down 1.6%

PBYI stock opened at $5.03 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.73 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average price of $4.09 and a two-hundred day moving average price of $3.51. The company has a market cap of $253.36 million, a price-to-earnings ratio of 5.13 and a beta of 1.38. Puma Biotechnology, Inc. has a twelve month low of $2.22 and a twelve month high of $6.07.

Analyst Ratings Changes

Separately, Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Friday. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $7.00.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 25,592 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total value of $90,339.76. Following the completion of the transaction, the chief executive officer directly owned 7,202,481 shares in the company, valued at $25,424,757.93. This trade represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Alessandra Cesano sold 27,000 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $3.37, for a total value of $90,990.00. Following the completion of the sale, the director directly owned 41,850 shares of the company's stock, valued at approximately $141,034.50. The trade was a 39.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 173,649 shares of company stock valued at $596,914. 23.30% of the stock is owned by insiders.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.